Some component of this panel might be part of the comprehensive metabolic panel.
Rule out cancer of islet cells.
Ruel out liver disease.
EGFR is expressed 30-50% in Pancreatic ductal adenocarcinoma (PDAC). http://www.ncbi.nlm.nih.gov/pubmed/26361407
Not specific for pancreas cancer, but helpful in therapy treatment.
In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.
Alternative to Comprehensive Metabolic Panel.
Alternative to hepatic liver panel.
Early detection of pancreatic cancer.
Chemotherapy monitoring.
Determine therapeutic strategy for cancer therapeutics such as Tegafur.
Rule out gastrointestinal cancer and bleeding.
Early detection and interval screening of high-risk individuals for pancreatic cancer.
Early detection of pancreatic cancer.
Please use “Pain Management Pharmacogenetics Gene Variation Panel” if testing ordered for pain management. This panel is comprehensive, and it is general and not specific for pain management.
Used in prognosis of malignancy.
Therapy selection and management.
If iron is low due to anemia.
Therapy monitoring.
If hemoglobin is low due to anemia.
If hemoglobin is low due to anemia.
Aid in the diagnosis and management.
Supportive in diagnosis and treatment.
Supportive in diagnosis and treatment.
Supportive in diagnosis and treatment.
Supportive in diagnosis and treatment.
Therapy selection and monitoring.
Rule out hepatocellular carcinoma.
In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.
In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.
In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.
Immunotherapy selection screen.
Alternative to specific genetic markers. Good for therapy selection and monitoring.
Alternative to specif gene markers. Good for therapy selection and monitoring.
Tempus’ PurISTSM test identifies the molecular subtype of patients with unresectable stage III or stage IV pancreatic ductal adenocarcinoma.
IF iron is low due to anemia.
Individual cancer test tissue specific is recommended.
Not covered by Medicare, LCD L39365.